HJ Research delivers in-depth insights on the global Neuropathic Pain Drugs market in its upcoming report titled, Global Neuropathic Pain Drugs Market Report 2018-2029. According to this study, the global Neuropathic Pain Drugs market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on Neuropathic Pain Drugs market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the Neuropathic Pain Drugs market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Neuropathic Pain Drugs industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Neuropathic Pain Drugs industry.
Global Neuropathic Pain Drugs market: competitive landscape analysis
This report contains the major manufacturers analysis of the global Neuropathic Pain Drugs industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global Neuropathic Pain Drugs market: types and end industries analysis
The research report includes specific segments such as end industries and product types of Neuropathic Pain Drugs. The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Neuropathic Pain Drugs market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of Neuropathic Pain Drugs in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global Neuropathic Pain Drugs market include:
Pfizer
Johnson & Johnson
Sanofi
GlaxoSmithKline
Eli Lilly
Bristol-Myers Squibb
Biogen
Baxter Healthcare
Depomed
Market segmentation, by product types:
Tricyclic Anti-Depressants Anticonvulsants
Serotonin-Norepinephrine Reuptake Inhibitor
Capsaicin Cream
Local Anaesthesia
Opioids
Steroids
Others
Market segmentation, by applications:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
1 Industry Overview of Neuropathic Pain Drugs
1.1 Research Scope
1.2 Market Segmentation by Types of Neuropathic Pain Drugs
1.3 Market Segmentation by End Users of Neuropathic Pain Drugs
1.4 Market Dynamics Analysis of Neuropathic Pain Drugs
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of Neuropathic Pain Drugs Industry
2.1 Pfizer
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Johnson & Johnson
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 Sanofi
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 GlaxoSmithKline
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Eli Lilly
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Bristol-Myers Squibb
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Biogen
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.7.4 Contact Information
2.8 Baxter Healthcare
2.8.1 Company Overview
2.8.2 Main Products and Specifications
2.8.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.8.4 Contact Information
2.9 Depomed
2.9.1 Company Overview
2.9.2 Main Products and Specifications
2.9.3 Neuropathic Pain Drugs Revenue and Gross Margin (2018-2023)
2.9.4 Contact Information
3 Global Neuropathic Pain Drugs Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of Neuropathic Pain Drugs by Regions (2018-2023)
3.2 Global Sales Revenue of Neuropathic Pain Drugs by Manufacturers (2018-2023)
3.3 Global Sales Revenue of Neuropathic Pain Drugs by Types (2018-2023)
3.4 Global Sales Revenue of Neuropathic Pain Drugs by End Users (2018-2023)
4 Northern America Neuropathic Pain Drugs Market Analysis by Countries, Types and End Users
4.1 Northern America Neuropathic Pain Drugs Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America Neuropathic Pain Drugs Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America Neuropathic Pain Drugs Sales Revenue Analysis by End Users (2018-2023)
4.4 United States Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
4.5 Canada Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5 Europe Neuropathic Pain Drugs Market Analysis by Countries, Types and End Users
5.1 Europe Neuropathic Pain Drugs Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe Neuropathic Pain Drugs Sales Revenue Analysis by Types (2018-2023)
5.3 Europe Neuropathic Pain Drugs Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.5 France Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.6 UK Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.7 Italy Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.8 Russia Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.9 Spain Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
5.10 Netherlands Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6 Asia Pacific Neuropathic Pain Drugs Market Analysis by Countries, Types and End Users
6.1 Asia Pacific Neuropathic Pain Drugs Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Neuropathic Pain Drugs Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Neuropathic Pain Drugs Sales Revenue Analysis by End Users (2018-2023)
6.4 China Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.5 Japan Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.6 Korea Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.7 India Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.8 Australia Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.9 Indonesia Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
6.10 Vietnam Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
7 Latin America Neuropathic Pain Drugs Market Analysis by Countries, Types and End Users
7.1 Latin America Neuropathic Pain Drugs Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America Neuropathic Pain Drugs Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America Neuropathic Pain Drugs Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
7.5 Mexico Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
7.6 Argentina Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
7.7 Colombia Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
8 Middle East & Africa Neuropathic Pain Drugs Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa Neuropathic Pain Drugs Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Neuropathic Pain Drugs Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Neuropathic Pain Drugs Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
8.6 South Africa Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
8.7 Egypt Neuropathic Pain Drugs Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global Neuropathic Pain Drugs Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of Neuropathic Pain Drugs by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of Neuropathic Pain Drugs by Types (2024-2029)
10.3 Global Sales Revenue Forecast of Neuropathic Pain Drugs by End Users (2024-2029)
10.4 Global Revenue Forecast of Neuropathic Pain Drugs by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of Neuropathic Pain Drugs
11.1 Upstream Analysis of Neuropathic Pain Drugs
11.2 Downstream Major Consumers Analysis of Neuropathic Pain Drugs
11.3 Major Suppliers of Neuropathic Pain Drugs with Contact Information
11.4 Supply Chain Relationship Analysis of Neuropathic Pain Drugs
12 Neuropathic Pain Drugs New Project Investment Feasibility Analysis
12.1 Neuropathic Pain Drugs New Project SWOT Analysis
12.2 Neuropathic Pain Drugs New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 Neuropathic Pain Drugs Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of Neuropathic Pain Drugs
Table End Users of Neuropathic Pain Drugs
Figure Market Drivers Analysis of Neuropathic Pain Drugs
Figure Market Challenges Analysis of Neuropathic Pain Drugs
Figure Market Opportunities Analysis of Neuropathic Pain Drugs
Table Market Drivers Analysis of Neuropathic Pain Drugs
Table Pfizer Information List
Figure Neuropathic Pain Drugs Specifications of Pfizer
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Pfizer (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Pfizer (2018-2023)
Table Johnson & Johnson Information List
Figure Neuropathic Pain Drugs Specifications of Johnson & Johnson
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Johnson & Johnson (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Johnson & Johnson (2018-2023)
Table Sanofi Information List
Figure Neuropathic Pain Drugs Specifications of Sanofi
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Sanofi (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Sanofi (2018-2023)
Table GlaxoSmithKline Information List
Figure Neuropathic Pain Drugs Specifications of GlaxoSmithKline
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of GlaxoSmithKline (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of GlaxoSmithKline (2018-2023)
Table Eli Lilly Information List
Figure Neuropathic Pain Drugs Specifications of Eli Lilly
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Eli Lilly (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Eli Lilly (2018-2023)
Table Bristol-Myers Squibb Information List
Figure Neuropathic Pain Drugs Specifications of Bristol-Myers Squibb
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Bristol-Myers Squibb (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Bristol-Myers Squibb (2018-2023)
Table Biogen Information List
Figure Neuropathic Pain Drugs Specifications of Biogen
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Biogen (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Biogen (2018-2023)
Table Baxter Healthcare Information List
Figure Neuropathic Pain Drugs Specifications of Baxter Healthcare
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Baxter Healthcare (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Baxter Healthcare (2018-2023)
Table Depomed Information List
Figure Neuropathic Pain Drugs Specifications of Depomed
Table Neuropathic Pain Drugs Revenue (Million USD) and Gross Margin of Depomed (2018-2023)
Figure Neuropathic Pain Drugs Revenue (Million USD) and Global Market Share of Depomed (2018-2023)
Table Global Revenue (Million USD) of Neuropathic Pain Drugs by Regions (2018-2023)
Table Global Revenue (Million USD) of Neuropathic Pain Drugs by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of Neuropathic Pain Drugs by Types (2018-2023)
Table Global Revenue (Million USD) of Neuropathic Pain Drugs by End Users (2018-2023)
Table Northern America Neuropathic Pain Drugs Revenue (Million USD) by Countries (2018-2023)
Table Northern America Neuropathic Pain Drugs Revenue (Million USD) by Types (2018-2023)
Table Northern America Neuropathic Pain Drugs Revenue (Million USD) by End Users (2018-2023)
Figure United States Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe Neuropathic Pain Drugs Revenue (Million USD) by Countries (2018-2023)
Table Europe Neuropathic Pain Drugs Revenue (Million USD) by Types (2018-2023)
Table Europe Neuropathic Pain Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Germany Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure France Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific Neuropathic Pain Drugs Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific Neuropathic Pain Drugs Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific Neuropathic Pain Drugs Revenue (Million USD) by End Users (2018-2023)
Figure China Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure India Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America Neuropathic Pain Drugs Revenue (Million USD) by Countries (2018-2023)
Table Latin America Neuropathic Pain Drugs Revenue (Million USD) by Types (2018-2023)
Table Latin America Neuropathic Pain Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Brazil Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa Neuropathic Pain Drugs Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa Neuropathic Pain Drugs Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa Neuropathic Pain Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Turkey Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of Neuropathic Pain Drugs by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of Neuropathic Pain Drugs by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of Neuropathic Pain Drugs by End Users (2024-2029)
Table Major Consumers with Contact Information of Neuropathic Pain Drugs
Table Major Suppliers of Neuropathic Pain Drugs with Contact Information
Figure Supply Chain Relationship Analysis of Neuropathic Pain Drugs
Table New Project SWOT Analysis of Neuropathic Pain Drugs
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of Neuropathic Pain Drugs
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of Neuropathic Pain Drugs Industry
Table Part of References List of Neuropathic Pain Drugs Industry
Table Units of Measurement List
Table Part of Author Details List of Neuropathic Pain Drugs Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Neuropathic Pain Drugs industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the Neuropathic Pain Drugs market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from Neuropathic Pain Drugs manufacturers, Neuropathic Pain Drugs raw material suppliers, Neuropathic Pain Drugs distributors as well as buyers. The primary sources from the supply side include Neuropathic Pain Drugs manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the Neuropathic Pain Drugs raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: Neuropathic Pain Drugs industry landscape and trends, Neuropathic Pain Drugs market dynamics and key issues, Neuropathic Pain Drugs technology landscape, market opportunities, porter’s analysis and PESTEL analysis, Neuropathic Pain Drugs competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: Neuropathic Pain Drugs market size and forecast by regions, Neuropathic Pain Drugs market size and forecast by application, Neuropathic Pain Drugs market size and forecast by types, Neuropathic Pain Drugs company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
